Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective

References

• World Cancer Research Fund International. Liver cancer statistics; 2022. Available from: https://www.wcrf.org/cancer-trends/liver-cancer-statistics/. Accessed September 15, 2023.
   Google Scholar
• Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–1556. doi:10.1016/j.jhep.2023.06.003
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49(5):1682–1699. doi:10.1007/s00259-021-05600-z
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
   PubMed Web of Science ®Google Scholar
• Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label Phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17–29. doi:10.1016/S2468-1253(20)30290-9
   PubMed Web of Science ®Google Scholar
• German national institute for quality and efficiency in health care (IQWiG). General Methods for the Assessment of the Relation of Benefits to Costs (Version 6.1); 2022. Available from: https://www.iqwig.de/methoden/general-methods_version-6-1.pdf. Accessed June 15, 2023.
   Google Scholar
• Woods BS, Sideris E, Palmer S, Latimer N, Soares M. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1613–1621. doi:10.1016/j.jval.2020.08.2094
   PubMed Web of Science ®Google Scholar
• Gaugain L, Cawston H, Dubois de Gennes C, et al. Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France. PLoS One. 2023;18(1):e0280442. doi:10.1371/journal.pone.0280442
   PubMed Web of Science ®Google Scholar
• Destatis Statistisches Bundesamt. Bevölkerungsstand: amtliche Einwohnerzahl Deutschlands; 2022. Available from: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bevoelkerung/Bevoelkerungsstand/_inhalt.html. Accessed August 19, 2023.
   Google Scholar
• Bundesgesundheitsministerium. Gesetzliche Krankenversicherung; Mitglieder, mitversicherte Angehörige und Krankenstand; 2023. Available from: https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Statistiken/GKV/Mitglieder_Versicherte/KM1_Januar_bis_Mai_2023_bf.pdf. Accessed August 19, 2023.
   Google Scholar
• Clouth J, Liepa AM, Moeser G, et al. Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data. Health Econ Rev. 2018;8(1):18. doi:10.1186/s13561-018-0199-1
   PubMedGoogle Scholar
• Weinmann A, Koch S, Sprinzl M, et al. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int. 2015;35(2):591–600. doi:10.1111/liv.12696
   PubMed Web of Science ®Google Scholar
• Institut für das Entgeltsystem im Krankenhaus. InEK DatenBrowser; 2019. Available from: https://datenbrowser.inek.org/. Accessed August 19, 2023.
   Google Scholar
• Lauer-Taxe - Standardwerk der Arzneimittelinformationen. Arzneimittelkosten Atezolizumab und Bevacizumab; 2023. Available from: https://portal.cgmlauer.cgm.com/LF/Seiten/Verwaltung/Kundencenter/1.aspx. Accessed June 15, 2023.
   Google Scholar
• Institut für das Entgeltsystem im Krankenhaus. Fallpauschalen-Katalog; 2023. Available from: https://www.g-drg.de/ag-drg-system-2023/fallpauschalen-katalog/fallpauschalen-katalog-20232. Accessed August 19, 2023.
   Google Scholar
• Pollock RF, Colaone F, Guardiola L, Shergill S, Brennan VK. A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. J Med Econ. 2020;23(6):593–602. doi:10.1080/13696998.2020.1731213
   PubMed Web of Science ®Google Scholar
• Marqueen KE, Kim E, Ang C, Mazumdar M, Buckstein M, Ferket BS. Cost-effectiveness analysis of selective internal radiotherapy with yttrium-90 versus sorafenib in locally advanced hepatocellular carcinoma. JCO Oncol Pract. 2021;17(2):e266–e277. doi:10.1200/OP.20.00443
   PubMedGoogle Scholar
• Destatis Statistisches Bundesamt. Kosten der stationären Krankenhausversorgung; 2023. Available from: https://www.destatis.de/DE/Presse/Pressemitteilungen/2021/04/PD21_194_231.html. Accessed August 19, 2023.
   Google Scholar
• Kaier K, Heister T, Wolff J, Wolkewitz M. Mechanical ventilation and the daily cost of ICU care. BMC Health Serv Res. 2020;20(1):267. doi:10.1186/s12913-020-05133-5
   PubMed Web of Science ®Google Scholar
• Amdahl J, Diaz J, Park J, Nakhaipour HR, Delea TE. Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol. 2016;23(4):e340–354. doi:10.3747/co.23.2244
   PubMed Web of Science ®Google Scholar
• Howell TA, Matza LS, Jun MP, Garcia J, Powers A, Maloney DG. Health State utilities for adverse events associated with chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Pharmacoecon Open. 2022;6(3):367–376. doi:10.1007/s41669-021-00316-0
   PubMed Web of Science ®Google Scholar
• Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making. 1985;5(2):157–177. doi:10.1177/0272989X8500500205
   PubMedGoogle Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.2291
   PubMed Web of Science ®Google Scholar
• Wetterwald L, Riggi N, Kyriazoglou A, Dei Tos G, Dei Tos A, Digklia A. Clear cell sarcoma: state-of-The art and perspectives. Expert Rev Anticancer Ther. 2023;23(3):235–242. doi:10.1080/14737140.2023.2183846
   PubMed Web of Science ®Google Scholar
• D’Avola D, Granito A, Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022;76(5):1185–1198. doi:10.1016/j.jhep.2021.11.013
   PubMed Web of Science ®Google Scholar